Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Merlière

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Revue D'Epidemiologie Et De Sante Publique|July 6, 2010
French national health insurance information system and the permanent beneficiaries sampleP Tuppin, L de Roquefeuil, A Weill, et al.
Pharmacoepidemiology and Drug Safety|November 24, 2006
The CADEUS study: methods and logisticsF Depont, A Fourrier, Y Merlière, et al.
Intensive Care Medicine|July 29, 1998
Estimation of direct cost and resource allocation in intensive care: correlation with Omega systemM Sznajder, G Leleu, G Buonamico, et al.
Pharmacoepidemiology and Drug Safety|March 14, 2007
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) studyF Depont, A Fourrier, Y Merlière, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Revue D'Epidemiologie Et De Sante Publique|July 6, 2010
French national health insurance information system and the permanent beneficiaries sampleP Tuppin, L de Roquefeuil, A Weill, et al.
Pharmacoepidemiology and Drug Safety|November 24, 2006
The CADEUS study: methods and logisticsF Depont, A Fourrier, Y Merlière, et al.
Intensive Care Medicine|July 29, 1998
Estimation of direct cost and resource allocation in intensive care: correlation with Omega systemM Sznajder, G Leleu, G Buonamico, et al.
Pharmacoepidemiology and Drug Safety|March 14, 2007
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) studyF Depont, A Fourrier, Y Merlière, et al.
Pageof 1